AXLRx · Disease Landscape Brief
How the NSCLC population segments by histology, stage, and biomarker — and where each segment is actually treated — before you size a single opportunity.
Why The Landscape Comes First
Non-small cell lung cancer accounts for roughly 85% of lung cancer. But "NSCLC" is a label over a dozen actionable molecular segments — EGFR, ALK, KRAS G12C, ROS1, PD-L1 tiers — each with a different dominant therapy and a different patient volume. Sizing the wrong segment is the most common pre-launch error.
Testing penetration determines how many of those biomarker-defined patients are actually identified and treatable. The gap between the epidemiological population and the tested, eligible population is where most addressable-market estimates break.
Below, we segment the population the way your commercial model has to — and show where the data is solid and where it is assumption.
What Your Team Needs Answered
Structured by decision, not by topic — every section feeds a specific commercial call.
Inside the Brief
What your team receives. Section scope is built around your asset and proposed label — not pulled from a generic template.
All deliveries include a 30-minute call with your analyst — to walk through findings and identify what your team needs to resolve next.
What You Receive
The intelligence analysis, the working model, and the board summary — delivered together.
Structured for sequential reading by your launch lead, medical affairs director, and market access team. Every exhibit sourced.
A live, editable model that splits the NSCLC population by histology, stage, and biomarker — with labelled, sourced assumptions your analyst can adjust.
Five slides your leadership team can act on — structured around decisions, not descriptions.
Sample Output
Illustrative segmentation. Prevalence ranges are segment-typical and shown to demonstrate the depth and sourcing standard your team receives — every figure on a commissioned brief is cited at the exhibit foot.
| Segment | Approx. share of NSCLC | Dominant 1L approach | Identification depends on | Commercial note |
|---|---|---|---|---|
| EGFR-mutantAdenocarcinoma-skewed | ~15% (US) | EGFR TKI (osimertinib) | NGS / EGFR testing at dx | Crowded; resistance-setting opportunity |
| ALK-positiveYounger, never-smoker skew | ~4% | ALK TKI | FISH / NGS | Small but high-value, durable |
| KRAS G12CSmoking-associated | ~13% | Chemo-IO; emerging G12C inhibitors | NGS | Active pipeline battleground |
| PD-L1 high (≥50%), no driverSee CI brief | ~25–30% of non-driver | IO monotherapy | PD-L1 IHC | IO incumbent-dominated |
| [YOUR SEGMENT][Client] · Confidential | Defined at intake | Scope-dependent | Per proposed biomarker | Sized to your asset |
Source Standard
This is a field where AI confidently reproduces outdated epidemiology, superseded payer policy, and retracted analyses. AXLRx uses none of its own memory as a source. Every figure your team receives is verified against a live document at the time of writing.
A wrong number in front of your payer or your leadership team is not recoverable in the same meeting.
Questions
Commission Your Analysis
We build from your asset's clinical profile — mechanism, biomarker strategy, proposed label, and target cohort. Scope confirmation takes one call.
Start Your RequestOr see a sample output to review the depth before committing.
Drug, mechanism, proposed indication, target cohort, geography. Five minutes via the intake form.
We confirm scope with your team, clarify ambiguities, and lock delivery timing.
PDF intelligence document, Excel model, and optional executive deck — with a 30-minute readout call included.